ArticleUrolithiasis2025
Effect of the plasma metabolites, biomarkers, and inflammatory proteins on urolithiasis: insights from Mendelian randomization and mediation analysis.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Urolithiasis represents a systemic disorder characterized by metabolic circulation issues and ongoing inflammation. The purpose of this research is to explore the relationships of causation among plasma metabolites, biomarkers, inflammatory proteins, and stones within the urinary system. We initially carried out a two-sample Mendelian randomization (MR) analysis to evaluate possible causal connections between 233 plasma metabolites and 35 biomarkers related to urolithiasis. The genetic association study (GWAS) data concerning plasma metabolites were derived from a 2024 publication in Nature, while data for biomarkers were collected from the UK Biobank. To determine causal relationships, we utilized several analytical techniques, including inverse variance weighting (IVW), MR-Egger, weighted median, and weighted mode. Furthermore, we conducted analyses for pleiotropy and heterogeneity to ensure the findings' robustness. A Steiger analysis was used to explore the presence of any reverse causal relationships. Lastly, we conducted mediation analysis to elucidate how inflammatory proteins mediate the associations between plasma metabolites, biomarkers, and stones in the urinary system. Our research demonstrates causal connections between six plasma metabolites and six biomarkers related to upper urinary tract stones. Furthermore, we identified causal associations between ten plasma metabolites and four biomarkers linked to lower urinary tract stones. Most of these metabolites belong to lipid and lipoprotein classes, indicating that changes in blood lipid levels may influence stone formation. Finally, mediation analysis revealed 13 mediating relationships, including the mediating effects of six inflammatory proteins. Our results provide evidence for the causal links among plasma metabolites, biomarkers, and inflammatory proteins associated with urolithiasis. This provides new insights into the potential mechanisms underlying urinary system stone formation, contributing to their prevention, diagnosis, and treatment.
Indexed as
Identifiers
40167789What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.